

1 **A cross-sectional study of Q fever in Camels: risk factors for infection, the role of small**
2 **ruminants and public health implications for desert-dwelling pastoral communities**

3 Peter Holloway^{1*}, Matthew Gibson¹, Stephen Nash², Tanja Holloway², Jacqueline Cardwell¹, Bilal
4 Al Omari³, Ehab Abu-Basha³, Punam Mangtani² and Javier Guitian¹

5 ¹ The Royal Veterinary College, Hatfield, AL9 7TA, UK (P. Holloway, M. Gibson, J. Cardwell, J. Guitian)

6 ² London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK (P. Mangtani, S. Nash, T. Holloway)

7 ³ Jordan University of Science and Technology, Ar-Ramtha, 3030, Jordan (E. Abu-Basha, B. Al-Omari).

8

9 **Keywords:** Q fever, *C.burnetii*, camels, risk factors, epidemiology, Jordan

10

11 **Abstract**

12 Q fever represents an important ‘neglected zoonosis’, with high prevalences recorded
13 across the Middle East region. Among rural desert-dwelling communities in the region, camel
14 milk is largely consumed raw, due to perceptions of dromedaries as a uniquely clean livestock
15 species mentioned in the Qur’an and Islamic hadith, while milk from other livestock species is
16 usually boiled. As a result, camels present a unique public health threat among such communities
17 from milk-borne pathogens, including *C. burnetii*. In view of this, an epidemiological survey was
18 conducted among dromedary herds in southern Jordan between September 2017 and October
19 2018, including 404 camels from 121 randomly selected herds. In addition, 510 household
20 members associated with these herds were interviewed regarding potential high-risk practices
21 for zoonotic transmission. Weight adjusted camel population seroprevalence for *C. burnetii* was
22 49.6% (95% CI: 44.7 – 54.5), with evidence of maternally derived immunity in calves ≤ 6 months
23 old. Adjusted herd-level prevalence was 76.0% (95%CI 72.7–80.2), with 30.4% (144/477) of
24 individuals estimated to consume raw milk from infected herds monthly or more. Following
25 multivariable logistic regression analysis, seropositive status in camels was found to be
26 associated with increasing age, high herd tick burdens, keeping the herd together throughout the
27 year including when calving, and owning larger (>50) sheep and goat flocks, with goats presenting
28 a higher risk than sheep. Racing camel status was found to be protective. Socioculturally

29 appropriate interventions aimed at raising awareness of potential risks associated with drinking
30 raw camel milk, alongside appropriate livestock management interventions, should be
31 considered.

32

33 **Introduction**

34 Q fever represents an important ‘neglected zoonosis’, which despite the presence of
35 licensed vaccines, remains largely unrecognized and uncontrolled, particularly among lower and
36 middle-income countries (LMIC) where seroprevalences are often high (1). The causative agent,
37 *Coxiella burnetii*, is an obligate gram-negative intracellular bacterium of high tenacity, favouring
38 hot dry conditions, with high infectivity (2). Human infections range from being asymptomatic to
39 causing an acute non-specific febrile illness, often with hepatitis and atypical pneumonia (3).
40 While most clinical infections are self-limiting, some individuals go on to develop chronic disease,
41 which may include endocarditis and fatigue (4,5). These non-specific and diverse signs and
42 symptoms, compounded by a lack of awareness among many healthcare workers and lack of
43 routine laboratory testing in many LMIC settings, mean that individuals presenting with clinical
44 *Coxiella burnetii* infection are frequently misdiagnosed (6,7).

45 In ruminants, Q fever is an important production disease causing reproductive losses
46 through abortions, stillbirths and infertility, alongside milk drop and chronic mastitis (8). Bacteria
47 are shed in high numbers through infected birth products, as well as in milk, faeces and urine (9).
48 Livestock and human infections occur via inhalation of contaminated dust particles, including
49 infected tick faeces, as well as through contact with infected birthing products and from infected
50 tick bites (10). Zoonotic transmission also occurs via consumption of infected raw dairy products
51 (11). While the zoonotic impact of *C. burnetii* infection in small ruminant and cattle populations
52 has been widely reported, the potential role of camels in zoonotic transmission of Q fever
53 remains largely unexamined, particularly in the Middle East region, where favourable conditions
54 for the pathogen exist (12). The widespread consumption of raw camel milk across the Arab
55 world, due to the perceptions of camels as uniquely clean livestock with mention in the Qur’an
56 and Islamic hadith, means that camels present a unique public health threat (13,14,15).

57 To improve understanding of the epidemiology and potential zoonotic risks posed by Q

58 fever in camels, we conducted a large-scale epidemiological survey among camel herds in
59 southern Jordan, largely owned by desert-dwelling Bedouin communities. This population is
60 considered likely to be representative of analogous Bedouin and pastoral communities in the
61 wider region. The objectives of the study were to: i) estimate the prevalence of *C. burnetii* in the
62 camel population in southern Jordan ii) identify potential transmission pathways for *C. burnetii*
63 infection in camels, particularly regarding the role of small ruminants, and iii) assess the potential
64 public health risk associated with these herds through consumption of raw milk and other
65 activities.

66


67 **Methods**

68 *Study design and study population*

69 A cross-sectional study was conducted between 28th October 2017 and 11th October to
70 2018, in Aqaba and Ma'an governorates of southern Jordan, an area of approximately 40,000
71 km² and 8,000 camels (based on MoA data) (figure 1). Probabilistic sampling was conducted
72 using camel owner lists supplied by the Ministry of Agriculture (MoA) according to four local
73 administrative areas (Aqaba east, Aqaba west, Ma'an east and Ma'an west). To facilitate owner
74 compliance no more than 12 camels were sampled per herd and in herds of less than 12 all camels
75 were sampled, subject to accessibility and owner permissions. Two standardised structured
76 questionnaires regarding potential risk factors for *C. burnetii* infection, in camels and humans
77 respectively, were administered in the local dialect on Android tablets, using the application
78 Open Data Kit (ODK), among herd owners and their household members. All camels included in
79 the study were clinically examined by a veterinary surgeon to assess general health and the
80 presence of ticks (yes/no), prior to collection of a serum sample.

81

82 *Figure 1. Location of 121 camel herds sampled in southern Jordan October 2017 to October 2018*
83 *(due to local grazing movements there were three herds selected from the MoA list for Ma'an*
84 *west that were sampled in the neighboring region, Tafilah. Results from these herds were*
85 *attributed to Ma'an west).*



86

87 *Laboratory methods*

88 Blood samples were collected in 8ml serum vacutainer tubes, transported in cool boxes
89 and centrifuged at 2000 RPM for 10 minutes, followed by serum collection and storage at -20°C.
90 Laboratory testing was performed at the Diagnostic Laboratory, Veterinary Health Centre, Jordan
91 University of Science and Technology, Ar-Ramtha, Irbid, using an indirect ELISA (ID Screen Q fever
92 Indirect Multi-species, IDVet, Montpellier, France). Plates were read at 405 nm and samples with
93 an optical density (OD) of $\geq 50\%$ were considered positive, according to the manufacturer's
94 recommendations. Sensitivity and specificity were reported by the manufacturer as being
95 approximately 100%; however, although widely used in camelids, the test has only been
96 validated for use in sheep, goats and cattle (16).

97

98 *Statistical analysis*

99 We calculated seroprevalence estimates, weighted according to sample size, relative to
100 the estimated camel population, based on MoA data for each sub-region. Regression models

101 were built for identification of risk factors, with camels ≤ 6 months of age excluded from analyses
102 due to the potential influence of maternally derived antibodies.

103 Univariable analyses were conducted, using mixed-effects logistic regression to adjust for
104 herd-level random effects, with camel serological status considered a binary outcome. All
105 potential risk factors were analysed as categorical variables, with the exception of camel age,
106 altitude of the holding, and small ruminant flock size which were analysed as continuous variables.
107 Season was not considered for analysis due to the non-longitudinal nature of the study and likely
108 correlation with sample location. A composite variable 'closed herd' was constructed, defined by
109 herd owners answering 'no' to borrowing, lending, purchasing, racing and contact with local or
110 distant herds.

111 Variables associated with the outcome with a p-value less than 0.2 were considered for
112 inclusion in the multivariable models, with the exception of any variables missing more than 10%
113 of their values. Collinearities between variables were examined using the Pearson R coefficient
114 and a threshold of 0.4, with collinear variables excluded from the same multivariable model.
115 Multivariable models were constructed using a backwards stepwise method, with the least
116 significant variable removed at each step while $p > 0.1$, unless the variable was considered an a
117 priori factor (sex and age) or the removal of the variable demonstrated a significant effect on the
118 other variables (a change in log odds $> 20\%$). Model building was repeated using a forwards
119 stepwise method, beginning with a priori variables and adding new variables in order of
120 significance, keeping variables if they showed $p < 0.1$ or changed the log odds of other risk factors
121 by $> 20\%$.

122 The herd-level prevalence of *C. burnetii* (the proportion of herds with at least one camel
123 with antibodies against *C. burnetii* in the serum) was estimated taking into account the
124 uncertainty arising from sampling of only a proportion of each herd (the proportion being
125 different in each herd). The following method was used, based on that described by Beauvais et
126 al. (17):

127 *Step 1.* For each herd, a probability distribution P_i , $i=0\dots m$ of the number of positive
128 animals (animals with serum antibodies) for herd size m was obtained as:

129
$$P_i = (Prior_i \times Likelihood_i) / \sum_{j=0\dots m} (Prior_j \times Likelihood_j)$$

130 where $Prior_i$ is the prior probability of having i positives in the herd, and $Likelihood_i$ is the
131 likelihood of having i positives given the sample results for that herd. Then, the probability of the
132 herd having at least one positive P_+ is $1-P_0$. The prior distribution for the number of positives in
133 the herd was calculated separately for each herd, as described by Beauvais et al (19). A frequency
134 distribution of within-herd prevalences was multiplied by the number of camels in the particular
135 herd, and the results were rounded to whole numbers to give a discrete probability distribution
136 for positives within the herd.

137 *Step 2.* Each herd was simulated as being positive or negative using a random sample from
138 a binomial distribution with probability of success P_+ . This was repeated 10000 times to create
139 an uncertainty distribution, where the 2.5th and 97.5th percentiles give a 95% credible interval
140 and the 50th percentile gives the most likely herd-level prevalence.

141 The number of individuals living in households with Q fever positive herds was compared
142 against questionnaire data relating to potential pathways for *C. burnetii* zoonotic transmission,
143 by calling a herd positive when there was at least a 50% probability (with 95% confidence) of the
144 herd having at least one positive animal, using Bayesian probability. This figure was used to a
145 calculate the percentage of the sample population likely to have been exposed to potential *C.*
146 *burnetii* transmission via high-risk practices.

147 All statistical analyses were performed in R (version 3.5.6) with mixed-effects models
148 generated using the glmer function of the package lme4 (version 1.1-23).

149

150 *Informed consent*

151 Informed consent was obtained from all participating camel owners and household
152 members at the time of sampling. Institutional and national guidelines for care, use, and handling
153 of animals were followed at all times. Studies were conducted with institutional ethical review
154 board approval by the Royal Veterinary College, London School of Hygiene and Tropical Medicine
155 (London, UK) and Jordan University of Science and Technology (Irbid, Jordan).

156


157 **Results**

158 Blood samples were collected from 404 camels in 121 herds, with an average of 3.3
159 camels sampled per herd (median herd size 9, IQR 4 - 17). The questionnaire regarding potential
160 risk factors for infection in camels was administered to all 121 herd owners, while the
161 questionnaire regarding potential high-risk practices for human infection was administered to
162 510 members of camel-owning households (which included the 121 herd owners). Camel
163 numbers sampled were: Ma'an east 90 (29 herds), Ma'an west 69 (21 herds), Aqaba east 147 (36
164 herds) and Aqaba west 90 (35 herds). MoA records described an estimated 1909 camels (138
165 herds) in Ma'an East, 1405 camels (127 herds) in Ma'an West, 3563 camels (198 herds) Aqaba
166 East and 873 camels (119 herds) in Aqaba West. Model outcomes were thus weighted for each
167 region by 2.02, 0.65, 0.66, 0.80, respectively.

168 Of the 404 camels sampled there were 8 samples with insufficient serum. Of the
169 remaining 396 samples, 189 were seropositive for *C. burnetii*, giving an unadjusted
170 seroprevalence of 47.7% and a weighted seroprevalence of 49.6% (95% CI: 44.7 – 54.5). Of these,
171 39 camels were aged ≤ 6 months with 18 seropositive (46.2%), OR 5.1; 95% CI 2.1–12.8; $p < 0.01$
172 compared with camels >6 months –2 years of age of whom 14.5% (11 positive / 76 total) were
173 seropositive, with seroprevalence then increasing with age (figure 2). Following removal of calves
174 ≤ 6 months old from the data set, the adjusted seroprevalence was 49.3% (95% CI: 44.0 – 54.6)
175 among 119 herds. Ticks were observed on 226 (55.9%) of camels sampled.

176

177 *Figure 2. C. burnetii seroprevalence among camel populations in southern Jordan, October 2017 to*
178 *October 2018, stratified by age.*



179

180 Descriptive statistics and univariable model results are presented in table 1 and figure 2.

181 Significant correlations, where $R > 0.4$, were identified between the variables 'region' & 'altitude',
182 between 'herd owner has small ruminants (linear per 10)' and 'herd owner has >50 sheep' and
183 'herd owner has >50 goats', and between 'closed herd' and 'contact with local camels' (inverse).

184 Multivariable model results are shown in Table 2, with the variable, 'camel is a racing
185 camel' found to be protective (OR_{adj} 0.14; 95% CI 0.03–0.62; $p=0.012$). There was evidence of
186 positive association between *C. burnetii* seropositivity and increasing age, per year (OR_{adj} 1.26;
187 95% CI 1.14–1.42; $p < 0.001$), high herd tick burden (OR_{adj} 7.90; 95% CI 2.50–19.29; $p < 0.001$), herd
188 kept as a single group throughout the year (OR_{adj} 5.93; 95% CI 1.52–10.77; $p=0.006$). While simply
189 owning sheep and goats was not significantly (< 0.05) associated with risk, increasing flock size
190 (linear, per 10) (OR_{adj} 1.10; 95% CI 1.00–1.09; $p=0.037$), and owning larger flocks were associated:
191 flock size >50 goats (OR_{adj} 8.78; 95% CI 2.04–18.06; $p=0.001$) and flock size >50 sheep (OR_{adj} 5.22;
192 95% CI 1.20–11.24; $p=0.024$). Due to significant collinearity ($R > 0.4$), these latter two variables
193 were analysed in separate models, in place of the variable 'herd owner has small ruminants'

194 (linear, per 10); all other variables maintained in the final model continued to demonstrate
195 significant association ($p < 0.05$) with *C. burnetii* seropositivity. Also due to collinearity ($R > 0.4$), the
196 variables ‘closed herd’ and ‘contact with local herds’ were included in separate multivariable
197 models, though neither was maintained in the final model.

198 At the herd level, 76.0% (95% credible interval 72.7–80.2) were estimated as being
199 positive for Q fever (having at least one *C. burnetii* seropositive camel present in the herd). It was
200 estimated that 30.4% (145/477) of individuals in camel-owning households were frequently
201 (monthly or more often) drinking raw milk from (their own) Q fever positive herds. In addition,
202 in the past year, 18.8% (96/510) of individuals had been involved in calving camels, 16.7% (85/510)
203 in handling birthing products, 16.5% (84/510) in cleaning camel pens, 7.6% (39/510) in
204 slaughtering camels, 2.6% (13/494) in handling raw camel meat and 10.4% (53/510) had been
205 bitten by ticks (from their own *C. burnetii* positive herds) (table 3).

206

207 Discussion

208 High seroprevalences of *C. burnetii* are reported in human and livestock populations in the
209 Middle East, where a hot dry climate and open deserts, combined with high, localised small
210 ruminant populations, provide favourable conditions for transmission via dust and wind (18,19).
211 However, while the zoonotic risk of Q fever from small ruminants and cattle is well established,
212 the potential risk from camels in the region is poorly understood. The Qur’an describes camels
213 as demonstrating the wisdom and power of God, and the Islamic hadith describe the healing
214 benefits of drinking camels’ milk and urine – meaning that among rural communities in the Arab
215 world, camel milk is usually consumed raw, while the milk from sheep and goats is usually boiled
216 (15,20). However, high *C. burnetii* seroprevalences among camel populations in the region (18),
217 and detection of *C. burnetii* in raw camel milk samples collected in the region (21), suggest
218 consumption of raw camel milk may present an important determinant for Q fever among human
219 populations in the Middle East.

220 In desert-dwelling pastoral communities, camels and small ruminants are commonly kept
221 together, with potential for pathogen transmission between species (22). This means that
222 zoonotic pathogens such as *C. burnetii*, which can be transmitted from small ruminants to camels,

223 present a risk to households owning mixed flocks/herds of small ruminants and camels, via the
224 consumption of raw camel milk, even when milk from other livestock species is boiled. Lafi et al.
225 reported high *C. burnetii* seroprevalences in goats and sheep in Jordan, estimated at 43.3% and
226 27.0% respectively, and Obaidat et al. have reported a seroprevalence of 24.2% among human
227 populations in Jordan (18,23). While Q fever seroprevalences have been reported in camel
228 populations in Tunisia (44.4%), Egypt (21.9%) and Iran (28.7%), our study is the first to report a
229 seroprevalence estimate for camels in Jordan (49.6%; 95% CI: 44.7 – 54.5) (22, 24,25).

230 In the study population, almost a third of camel owners and their households were found
231 to be frequently drinking raw camel milk from *C. burnetii* positive herds. This indicates a clear
232 public health risk from Q fever in camels in the region – alongside other risk-associated camel-
233 engagement activities such as cleaning pens, handling afterbirth, facilitating calving, slaughtering,
234 handling raw meat or camel-tick bites (26,27). In addition, high *C. burnetii* seroprevalences in
235 camels suggest likely production losses through infertility, abortions, still-births, weak off-spring,
236 milk drop or chronic mastitis, all with important economic impact (8).

237 Where camels and small ruminants were owned together, simply owning sheep and/or
238 goats was not found to be associated with a significant increase in *C. burnetii* seroprevalence in
239 these camel herds. However, larger small ruminant flock sizes were significantly associated with
240 higher *C. burnetii* seroprevalence in camel herds associated with these flocks. Small ruminant
241 flock sizes of >50 sheep or goats were associated with increased *C. burnetii* seroprevalence in
242 associated herds. In addition, the risk associated with large goat flocks was greater than that
243 associated with large sheep flocks, this being consistent with higher seroprevalences previously
244 identified in goat flocks in the region, and with previous findings identifying goats as posing a
245 greater risk of *C. burnetii* infection than sheep (18,28).

246 Our study findings suggest that controlling Q fever in small ruminant populations is likely
247 to be important in reducing *C. burnetii* seroprevalence in associated camel populations. An
248 effective livestock vaccine for Q fever, Coxevac, manufactured by Ceva, Libourne, France), has
249 been used extensively in the Netherlands (29,30). The potential use of such a vaccine among
250 small ruminants and cattle in Jordan and the wider region should be considered. In addition,
251 efficacy studies for possible use of the vaccine in camels should be conducted. This study is the

252 first to demonstrate evidence of maternal antibodies to *C. burnetii* in camels, lasting until
253 approximately 6 months of age. This suggests that, when considering future efficacy studies for
254 existing *C. burnetii* vaccines in camels, vaccination should probably be delayed until after 6
255 months of age, with further research required. *C. burnetii* seroprevalence increased significantly
256 with camel age, consistent with increased risk of exposure over time and antibodies being long-
257 lasting, in keeping with other studies (22).

258 Due to the high shedding known to occur in small ruminant birthing and aborted materials,
259 small ruminant flocks should be separated from camel herds during the lambing/kidding period
260 where possible (26). Indeed, in view of *C. burnetii*'s ability to form tenacious spore-like cell
261 variants, capable of remaining in the environment for more than a year, separate birthing areas
262 for small ruminants and camels are advisable (8,26). As the pathogen can travel long distances
263 via the wind, these areas should be as far apart as possible, and moved regularly. The practice of
264 keeping herds together as a single group throughout the year was associated with significantly
265 higher *C. burnetii* seroprevalences in studied herds. This is likely explained by increased exposure
266 to infected camel birthing products in these herds, compared to herds where pregnant females
267 are removed prior to calving (26). This suggests removal of pregnant females from the herd prior
268 to calving as a potentially important management intervention in reducing *C. burnetii*
269 transmission between camels. The importance of herd owner hygiene through hand washing
270 (and use of disinfectant foot baths where practical) after working with small ruminants at
271 parturition time, should also be stressed. Such interventions also have relevance in protecting
272 camels (and individuals themselves) from other zoonoses in the region of public health concern,
273 particularly brucellosis, endemic in Jordan and the wider region (11,31,32).

274 Ticks are known to play an important role in *C. burnetii* transmission in livestock
275 populations globally (26). In our own study, a high herd tick burden (meaning all camels sampled
276 from the herd had ticks) was significantly associated with higher herd *C. burnetii* seroprevalences.
277 *C. burnetii* has been identified in camel ticks across Africa and the Middle East, particularly in
278 *Hyalomma ssp*, *Amblyomma spp*. and *Rhipicephalus spp*. (33,34). This suggests that aggressive
279 tick control, using frequent acaricide washes or pour-ons (for example monthly or every two
280 months), could play an important role in controlling Q fever in camel populations in Jordan and

281 the wider region; further research on this is required (35). In addition, parallel tick control in small
282 ruminant populations associated with these herds, for example through quarterly dipping, could
283 also be expected to offer a protective effect.

284 Seroprevalence in racing camels was significantly lower than in non-racing camels, likely
285 explained by separation of racing camels from the main herd and small ruminant flocks, for
286 training purposes. However, parturition during racing lifetime is limited, and racing camels are
287 not usually used in milk production, meaning lower *C. burnetii* seroprevalences are of limited
288 public health impact.

289 In conclusion, the high seroprevalence of *C. burnetii* in camel herds in southern Jordan
290 coupled with frequent consumption of camel milk and animal husbandry practices where
291 exposure to contaminated environment is high, indicates a clear public health risk. To reduce the
292 zoonotic risk, and to reduce potential production losses, the following targeted management
293 interventions aimed at limiting the transmission of *C. burnetii* in camels should be considered: i)
294 removal of breeding camels from the herd prior to calving, ii) creating separate birthing areas for
295 small ruminants and camels, as far apart as possible and moved regularly, iii) promoting owner
296 biosecurity measures that include hand hygiene (and use of disinfectant foot baths where
297 practical) after working with recently calved or aborted livestock or after handling aborted
298 material. Control measures in small ruminants are of particular importance when managing
299 camel herds alongside larger flocks, particularly regarding goats. Potential licensing and use of
300 existing *C. burnetii* vaccines in Jordan, for use in small ruminants (and cattle), should be
301 considered. In addition, efficacy studies regarding the use of such vaccines in camels should be
302 conducted.

303 Given the high percentage (over 30%) of individuals in camel-owning households drinking
304 raw camel milk from *C. burnetii* positive herds, educational efforts to promote boiling of camels'
305 milk should be encouraged. However, in view of the profound cultural barriers likely to be
306 encountered, detailed ethnographic studies to identify public health interventions that are
307 culturally appropriate should first be conducted. In summary, Q fever represents an important
308 zoonosis in the Middle East region and beyond, with high population seroprevalences previously
309 recorded. High *C. burnetii* seroprevalences identified in camels, alongside widespread

310 engagement in high-risk camel-associated practices, including consumption of raw milk, suggest
311 camels likely present a high-risk species for human infection, with culturally appropriate
312 veterinary and public health interventions urgently needed.

313

314 **Acknowledgements**

315 This research was partly supported by a Medical Research Council Global Challenges Research
316 Fund Foundation award 2017/18 study. The authors would like to sincerely thank the Ministry of
317 Agriculture in Jordan, in particular Dr Fares Ameen Altakhainah, Dr Ghassab Hatem Hasanat, Dr
318 Hassan Hassaen Alhusainat and Dr Abdalmajeed Mahmoud Alajjlouni.

319

320

321

322

323

324

325

326

327

328

329

330

331

332 *Table 1. Characteristics of study sample and univariate associations between potential risk factors and C.*
 333 *burnetii seropositivity in camel populations in southern Jordan, October 2017 to October 2018 (due to the*
 334 *potential influence of maternal immunity camels ≤6m have been excluded from all variables except age).*
 335

Variable	Category	Total (missing)	Positive	(%)	OR	(95% CI)	p value
Region	Aqaba	226	80	35%	6.73	(2.20–20.58)	<0.01
	Ma'an	131	91	69%			
Sub-region	Aqaba East	140	40	29%	1.00	–	<0.01
	Aqaba West	86	40	47%	4.08	(1.09–15.29)	
	Ma'an East	67	36	54%	5.78	(1.53 – 21.78)	
	Ma'an West	64	55	86%	68.44	(9.87–474.67)	
Altitude	(per 1000m)	–	–	–	2.62	(0.75–9.21)	0.13
Sex	Male	80	23	29%	1.00		0.04
	Female	277	148	53%	2.49	(1.04–5.97)	
Age	0 – 6m	39	18	46%	–	–	–
	6m – 2yr	76	11	14%	1.00		<0.01
	2yr – 4yr	58	24	41%	6.00	(1.61–22.37)	
	4yr – 6yr	74	37	50%	12.79	(3.47–47.10)	
	> 6yr	149	99	66%	24.85	(7.03–87.82)	
Age	(per year)	–	–	–	1.28	(1.15–1.42)	<0.01
Herd size	1–10	158	71	45%	1.00		0.43
	10–20	74	40	54%	2.29	(0.56–9.37)	
	>20	125	60	48%	1.84	(0.49–6.92)	
Herd size	(per 10 camels)	–	–	–	0.99	(0.80–1.23)	0.96
Number of camel herds nearby (within 15 minutes drive)	≤20	254	127	50%	0.75	(0.21–2.61)	0.65
	>20	103	44	43%			
Herd is kept together as single group throughout the year	No	106	35	33%	6.93	(2.25–21.41)	<0.01
	Yes	196	115	59%			

Contact with local herds	No	193	90	47%	2.17	(0.72–6.57)	0.17																																																																																																																																																				
	Yes	164	81	49%				Contact with distant herds (transhumance)	No	169	79	47%	2.02	(0.68–6.01)	0.21	Yes	188	92	49%	New camels are purchased	No	233	110	47%	0.84	(0.27–2.58)	0.76	Yes	124	61	49%	Some form of quarantine is practiced following purchase	No	100	50	50%	0.59	(0.04–7.94)	0.69	Yes	24	11	46%	Camels are borrowed for breeding purposes	No	204	96	47%	1.80	(0.60–5.37)	0.30	Yes	153	75	49%	Camels are lent for breeding purposes	No	199	97	49%	1.87	(0.61–5.69)	0.27	Yes	158	74	47%	Camel is a racing camel	No	271	146	54%	0.15	(0.03–0.63)	0.01	Yes	33	3	9%	Closed herd*	No	273	139	51%	0.29	(0.08–1.08)	0.07	Yes	84	32	38%	Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01	Yes	141	99	70%	Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%	>3	21	2	10%	Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%	>3	17	6	35%	Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57
Contact with distant herds (transhumance)	No	169	79	47%	2.02	(0.68–6.01)	0.21																																																																																																																																																				
	Yes	188	92	49%				New camels are purchased	No	233	110	47%	0.84	(0.27–2.58)	0.76	Yes	124	61	49%	Some form of quarantine is practiced following purchase	No	100	50	50%	0.59	(0.04–7.94)	0.69	Yes	24	11	46%	Camels are borrowed for breeding purposes	No	204	96	47%	1.80	(0.60–5.37)	0.30	Yes	153	75	49%	Camels are lent for breeding purposes	No	199	97	49%	1.87	(0.61–5.69)	0.27	Yes	158	74	47%	Camel is a racing camel	No	271	146	54%	0.15	(0.03–0.63)	0.01	Yes	33	3	9%	Closed herd*	No	273	139	51%	0.29	(0.08–1.08)	0.07	Yes	84	32	38%	Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01	Yes	141	99	70%	Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%		>3	21	2	10%				Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61		0-3	98	51	52%				>3	17	6	35%	Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%
New camels are purchased	No	233	110	47%	0.84	(0.27–2.58)	0.76																																																																																																																																																				
	Yes	124	61	49%				Some form of quarantine is practiced following purchase	No	100	50	50%	0.59	(0.04–7.94)	0.69	Yes	24	11	46%	Camels are borrowed for breeding purposes	No	204	96	47%	1.80	(0.60–5.37)	0.30	Yes	153	75	49%	Camels are lent for breeding purposes	No	199	97	49%	1.87	(0.61–5.69)	0.27	Yes	158	74	47%	Camel is a racing camel	No	271	146	54%	0.15	(0.03–0.63)	0.01	Yes	33	3	9%	Closed herd*	No	273	139	51%	0.29	(0.08–1.08)	0.07	Yes	84	32	38%	Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01	Yes	141	99	70%	Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%		>3	21	2	10%				Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%		>3	17	6	35%				Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%												
Some form of quarantine is practiced following purchase	No	100	50	50%	0.59	(0.04–7.94)	0.69																																																																																																																																																				
	Yes	24	11	46%				Camels are borrowed for breeding purposes	No	204	96	47%	1.80	(0.60–5.37)	0.30	Yes	153	75	49%	Camels are lent for breeding purposes	No	199	97	49%	1.87	(0.61–5.69)	0.27	Yes	158	74	47%	Camel is a racing camel	No	271	146	54%	0.15	(0.03–0.63)	0.01	Yes	33	3	9%	Closed herd*	No	273	139	51%	0.29	(0.08–1.08)	0.07	Yes	84	32	38%	Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01	Yes	141	99	70%	Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%		>3	21	2	10%				Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%		>3	17	6	35%				Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%																								
Camels are borrowed for breeding purposes	No	204	96	47%	1.80	(0.60–5.37)	0.30																																																																																																																																																				
	Yes	153	75	49%				Camels are lent for breeding purposes	No	199	97	49%	1.87	(0.61–5.69)	0.27	Yes	158	74	47%	Camel is a racing camel	No	271	146	54%	0.15	(0.03–0.63)	0.01	Yes	33	3	9%	Closed herd*	No	273	139	51%	0.29	(0.08–1.08)	0.07	Yes	84	32	38%	Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01	Yes	141	99	70%	Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%		>3	21	2	10%				Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%		>3	17	6	35%				Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%																																				
Camels are lent for breeding purposes	No	199	97	49%	1.87	(0.61–5.69)	0.27																																																																																																																																																				
	Yes	158	74	47%				Camel is a racing camel	No	271	146	54%	0.15	(0.03–0.63)	0.01	Yes	33	3	9%	Closed herd*	No	273	139	51%	0.29	(0.08–1.08)	0.07	Yes	84	32	38%	Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01	Yes	141	99	70%	Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%		>3	21	2	10%				Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%		>3	17	6	35%				Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%																																																
Camel is a racing camel	No	271	146	54%	0.15	(0.03–0.63)	0.01																																																																																																																																																				
	Yes	33	3	9%				Closed herd*	No	273	139	51%	0.29	(0.08–1.08)	0.07	Yes	84	32	38%	Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01	Yes	141	99	70%	Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%		>3	21	2	10%				Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%		>3	17	6	35%				Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%																																																												
Closed herd*	No	273	139	51%	0.29	(0.08–1.08)	0.07																																																																																																																																																				
	Yes	84	32	38%				Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01	Yes	141	99	70%	Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%		>3	21	2	10%				Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%		>3	17	6	35%				Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%																																																																								
Herd tick burden high**	No	216	72	33%	10.25	(3.31–31.69)	<0.01																																																																																																																																																				
	Yes	141	99	70%				Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15	1-3	68	24	35%		>3	21	2	10%				Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10	Yes	19	2	10%	Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%		>3	17	6	35%				Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%																																																																																				
Tick treatment: acaricide washes / year	0	253(15)	132	52%	1.00	(0.14–1.86)	0.15																																																																																																																																																				
	1-3	68	24	35%																																																																																																																																																							
	>3	21	2	10%																																																																																																																																																							
Tick treatment: >3 acaricide washes / year	No	321(15)	156	49%	0.08	(0.00–1.62)	0.10																																																																																																																																																				
	Yes	19	2	10%				Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61	0-3	98	51	52%	>3	17	6	35%	Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57	Yes	17	6	35%																																																																																																																								
Tick treatment: Ivermectin injections / year	0	227(15)	101	44%	1.00	(0.49–5.65)	0.61																																																																																																																																																				
	0-3	98	51	52%																																																																																																																																																							
	>3	17	6	35%																																																																																																																																																							
Tick treatment: >3 Ivermectin injections / year	No	325(15)	152	47%	0.48	(0.04–5.84)	0.57																																																																																																																																																				
	Yes	17	6	35%																																																																																																																																																							

Herd owner owns small ruminants†	(per 10 animals)	–	–	–	1.05	(1.01–1.10)	0.02
Herd owner owns sheep	No	105	50	48%	0.93	(0.28–3.07)	0.91
	Yes	252	121	48%			
Herd owner owns goats	No	46	23	50%	0.51	(0.11–2.38)	0.39
	Yes	311	148	48%			
Herd owner owns >50 sheep	No	260	107	41%	5.48	(1.61–18.66)	0.01
	Yes	97	64	66%			
Herd owner owns >50 goats	No	259	99	38%	8.64	(2.51–29.73)	<0.01
	Yes	98	72	73%			
Dog(s) present	No	42	19	45%	0.74	(0.15–3.77)	0.72
	Yes	315	152	48%			
Cat(s) observed	No	55	27	49%	1.94	(0.48–7.72)	0.35
	Yes	302	144	48%			
Rats / mice observed daily or weekly	No	217	97	45%	2.27	(0.76–6.82)	0.14
	Yes	140	74	53%			
Drinking source: Spring water	No	308	151	49%	0.95	(0.19–4.66)	0.95
	Yes	49	20	41%			
Drinking source: Irrigation reservoir	No	327	157	48%	4.93	(0.57–42.76)	0.15
	Yes	30	14	47%			
Drinking source: Tanker	No	241	115	48%	1.47	(0.45–4.74)	0.52
	Yes	116	56	48%			
Drinking source: Tap	No	192	96	50%	0.87	(0.29–2.63)	0.80
	Yes	165	75	45%			

Drinking source: Well	No	271	123	45%	2.15	(0.60–7.77)	0.24
	Yes	86	48	56%			
Water source not shared with the household	No	259	123	47%	0.63	(0.11–3.47)	0.58
	Yes	98	48	49%	0.61		
Shared water source‡	Open <i>ad lib</i>	53	24	45%	1.00		0.80
	not shared	98	48	49%	0.61	(0.11–3.47)	
	Trough only	206	99	48%	0.59	(0.12–2.89)	

*Closed herd = herds answering no to all of the following variables; borrowing, lending, purchasing, racing, contact with local and/or distant herds

** All camels sampled from the herd had ticks present at the time of sampling

†Up to flock size ≤500 (5 flocks of recorded flock size >1000 were excluded due to reasonable suspicion of inaccuracy)

‡Open *ad lib* = irrigation reservoir and/or spring water sources used, Household only = water source not shared between household and herd, Trough only = tanker and/or tap and/or well sources used only

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357
358
359
360

Table 2. Multivariable associations between potential risk factors and C. burnetii seropositivity in camel populations in southern Jordan, October 2017 to October 2018 (due to the potential influence of maternal immunity camels ≤6m have been excluded).

Variable	Category	A-priori adjusted OR (95% CI) ¹		p value	Fully adjusted OR (95% CI) ²		p value
Age	(per year)	1.26	(1.14–1.40)	<0.001	1.26	(1.14–1.42)	<0.001
Herd tick burden high*	Yes	7.90	(2.69–23.18)	<0.001	7.90	(2.50–19.29)	<0.001
Herd kept as single group all year	Yes	5.93	(2.06–17.10)	<0.001	5.93	(1.52–10.77)	0.006
Herd owner also owns small ruminants†	(per 10)	1.05	(1.01–1.09)	0.017	1.04	(1.00–1.09)	0.037
Camel is a racing camel	Yes	0.14	(0.03–0.63)	0.010	0.14	(0.03–0.62)	0.012
Sex	Female	1.62	(0.68–3.86)	0.281	1.62	(0.36–2.35)	0.874
Altitude**	(per 1000m)	1.90	(0.58–6.21)	0.286	–	–	–
Contact with local herds	Yes	1.86	(0.67–5.20)	0.237	–	–	–
Closed herd***	Yes	0.27	(0.08–0.93)	0.039	–	–	–
Tick treatment: >3 acaricide washes/ yr.	Yes	0.16	(0.01–2.88)	0.215	–	–	–
Rats / mice observed daily or weekly	Yes	2.19	(0.79–6.07)	0.131	–	–	–
Drinking source: Irrigation reservoir	Yes	7.23	(0.98–53.45)	0.053	–	–	–
Herd owner owns >50 goats†	Yes	8.78	(2.78–27.77)	0.010	8.78	2.04–18.06	0.001
Herd owner owns >50 sheep†	Yes	5.22	(1.66–16.38)	0.005	5.22	1.20–11.24	0.024

¹ Adjusted for a-priori variables; age and sex.

*All camels sampled from the herd had ticks

² Adjusted for; Sex, Age, Herd tick burden high, Herd kept as a single group all year, Herd own owns small ruminants, Camel is a racing camel.

**Due to significant collinearity ($R>0.4$) between 'region' and 'altitude', altitude was chosen over region for inclusion in the final model

***Closed herd = herds answering no to; 'borrowing, lending, purchasing, racing, contact with local and/or distant herds.' Due to significant collinearity ($R>0.4$), the variables 'closed herd' and 'contact with local herds' were included in separate multivariable models, though neither variable was maintained in the model.

†Due to significant collinearity ($R>0.4$) between the variables 'Herd owners owns small ruminants (linear, per 10)', 'Herd owner owns >50 sheep' and 'Herd owner owns >50 goats', these variables were included in separate multivariable models. In these models, all variables listed continued to demonstrate significant association ($p<0.05$) with *C. burnetii* seropositivity.

361

362

363

364

365

366

367

368

369

370

371

372

373 *Table 3. Percentage of study population exposed to potential C. burnetii transmission pathways, using a*
 374 *Bayesian method to predict positive herds with 95% confidence, among camel owning households in*
 375 *southern Jordan, October 2017 to October 2018 (due to the potential influence of maternal immunity,*
 376 *exposure to seropositive camels $\leq 6m$ was not included)*
 377

Variable	Category	No. of individuals within <i>C.burnetii</i> +ve herd households (missing)	No. of individuals within <i>C.burnetii</i> -ve herd households (missing)	No. of individuals exposed / total study population	% of camel owning population exposed																																																			
Drink raw camels' milk from own herd	Yes	145 (26)	47 (7)	145 / 477	30.4%																																																			
	No	207	78			Clean own camel pens	Yes	84	39	84 / 510	16.5%	No	294	93	Calve own camels	Yes	96	31	96 / 510	18.8%	No	282	101	Handle camel afterbirth	Yes	85	29	85 / 510	16.7%	No	293	103	Slaughter own camels	Yes	39	14	39 / 510	7.6%	No	339	118	Handling raw meat from own camels	Yes	13 (14)	7 (2)	13 / 494	2.6%	No	351	123	Bitten by ticks	Yes	53	6	53 / 510	10.4%
Clean own camel pens	Yes	84	39	84 / 510	16.5%																																																			
	No	294	93			Calve own camels	Yes	96	31	96 / 510	18.8%	No	282	101	Handle camel afterbirth	Yes	85	29	85 / 510	16.7%	No	293	103	Slaughter own camels	Yes	39	14	39 / 510	7.6%	No	339	118	Handling raw meat from own camels	Yes	13 (14)	7 (2)	13 / 494	2.6%	No	351	123	Bitten by ticks	Yes	53	6	53 / 510	10.4%	No	325	126						
Calve own camels	Yes	96	31	96 / 510	18.8%																																																			
	No	282	101			Handle camel afterbirth	Yes	85	29	85 / 510	16.7%	No	293	103	Slaughter own camels	Yes	39	14	39 / 510	7.6%	No	339	118	Handling raw meat from own camels	Yes	13 (14)	7 (2)	13 / 494	2.6%	No	351	123	Bitten by ticks	Yes	53	6	53 / 510	10.4%	No	325	126															
Handle camel afterbirth	Yes	85	29	85 / 510	16.7%																																																			
	No	293	103			Slaughter own camels	Yes	39	14	39 / 510	7.6%	No	339	118	Handling raw meat from own camels	Yes	13 (14)	7 (2)	13 / 494	2.6%	No	351	123	Bitten by ticks	Yes	53	6	53 / 510	10.4%	No	325	126																								
Slaughter own camels	Yes	39	14	39 / 510	7.6%																																																			
	No	339	118			Handling raw meat from own camels	Yes	13 (14)	7 (2)	13 / 494	2.6%	No	351	123	Bitten by ticks	Yes	53	6	53 / 510	10.4%	No	325	126																																	
Handling raw meat from own camels	Yes	13 (14)	7 (2)	13 / 494	2.6%																																																			
	No	351	123			Bitten by ticks	Yes	53	6	53 / 510	10.4%	No	325	126																																										
Bitten by ticks	Yes	53	6	53 / 510	10.4%																																																			
	No	325	126																																																					

378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390

391 **References**

392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434

1. Vanderburg S, Rubach MP, Halliday JE, Cleaveland S, Reddy EA, Crump JA. 2014. Epidemiology of *Coxiella burnetii* infection in Africa: a OneHealth systematic review. *PLoS neglected tropical diseases* 8:e2787.
2. Maurin, M. , & Raoult, D. (1999). Q fever. *Clinical Microbiology Reviews*, 12, 518.
3. van der Hoek W, Versteeg B, Meekelenkamp JC, Renders NH, Leenders AC, et al. (2011) Follow-up of 686 patients with acute Q fever and detection of chronic infection. *Clin Infect Dis* 52: 1431–1436.
4. Brouqui P, Dupont HT, Drancourt M, Berland Y, Etienne J, et al. (1993) Chronic Q fever. Ninety-two cases from France, including 27 cases without endocarditis. *Arch Intern Med* 153: 642–648.
5. Ayres JG, Flint N, Smith EG, Tunnicliffe WS, Fletcher TJ, et al. (1998) Post-infection fatigue syndrome following Q fever. *QJM* 91: 105–123.
6. Buijs SB, Bleeker-Rovers CP, van Roeden SE, Kampschreur LM, Hoepelman AIM, Wever PC, Oosterheert JJ. Still New Chronic Q Fever Cases Diagnosed 8 Years After a Large Q Fever Outbreak. *Clin Infect Dis*. 2021 Oct 20;73(8):1476-1483.
7. Honarmand H. Q Fever: an old but still a poorly understood disease. *Interdiscip Perspect Infect Dis*. 2012;2012:131932.
8. Overview of Coxiellosis - Generalized Conditions - MSD Veterinary Manual <https://www.msddvetmanual.com/generalized-conditions/coxiellosis/overview-of-coxiellosis>
9. Canevari JT, Firestone SM, Vincent G, Campbell A, Tan T, Muleme M, Cameron AWN, Stevenson MA. The prevalence of *Coxiella burnetii* shedding in dairy goats at the time of parturition in an endemically infected enterprise and associated milk yield losses. *BMC Vet Res*. 2018 Nov 20;14(1):353.
10. Angelakis E, Raoult D. Q Fever. *Vet Microbiol*. 2010 Jan 27;140(3-4):297-309.
11. Signs KA, Stobierski MG, Gandhi TN. Q fever cluster among raw milk drinkers in Michigan, 2011. *Clin Infect Dis*. 2012 Nov 15;55(10):1387-9.
12. Devaux CA, Osman IO, Million M, Raoult D. *Coxiella burnetii* in Dromedary Camels (*Camelus dromedarius*): A Possible Threat for Humans and Livestock in North Africa and the Near and Middle East? *Front Vet Sci*. 2020 Nov 5;7:558481.

- 435 13. Qur'an Surra 88, verses 17-20
436
- 437 14. Hadith Sahih Bukhari, Ablutions, Volume 1, Book 4, Number 234)
438
- 439 15. Galali Y, Al-Dmoor H. Miraculous Properties of Camel Milk and Perspective of Modern
440 Science J Fam Med Dis Prev 2019, 5:095
441
- 442 16. ID Screen® Rift Valley Fever Competition Multi-species, [https://www.id-](https://www.id-vet.com/produit/id-screen-rift-valley-fever-competition-multi-species/)
443 [vet.com/produit/id-screen-rift-valley-fever-competition-multi-species/](https://www.id-vet.com/produit/id-screen-rift-valley-fever-competition-multi-species/)
444
- 445 17. Beauvais W, Orynbayev M, & Guitian J. (2016). Empirical Bayes estimation of farm
446 prevalence adjusting for multistage sampling and uncertainty in test performance: a
447 *Brucella* cross-sectional serostudy in southern Kazakhstan. *Epidemiology and*
448 *infection*, 144(16), 3531–3539
449
- 450 18. Lafi SQ, Talafha AQ, Abu-Dalbouh MA, Hailat RS, Khalifeh MS. Seroprevalence and
451 associated risk factors of *Coxiella burnetii* (Q fever) in goats and sheep in northern Jordan.
452 *Trop Anim Health Prod.* 2020 Jul;52(4):1553-1559.
453
- 454 19. Ergas D, Keysari A, Edelstein V, Sthoeger ZM. Acute Q fever in Israel: clinical and
455 laboratory study of 100 hospitalized patients. *Isr Med Assoc J.* 2006 May;8(5):337-41.
456
- 457 20. Abdel Gader A, Alhaider A. The unique medicinal properties of camel products: A review
458 of the scientific evidence. *Journal of Taibah University Medical Sciences* (2016) 11(2),
459 98e103
460
- 461 21. Esmaeili S, Mohabati Mobarez A, Khalili M, Mostafavi E, Moradnejad P. Molecular
462 prevalence of *Coxiella burnetii* in milk in Iran: a systematic review and meta-analysis. *Trop*
463 *Anim Health Prod.* 2019 Jul;51(6):1345-1355.
464
- 465 22. Selim A, Ali AF. Seroprevalence and risk factors for *C. burentii* infection in camels in Egypt.
466 *Comp Immunol Microbiol Infect Dis.* 2020 Feb;68:101402.
467
- 468 23. Obaidat, M. M., Malania, L., Imnadze, P., Roess, A. A., Bani Salman, A. E., & Arner, R. J.
469 (2019). Seroprevalence and Risk Factors for *Coxiella burnetii* in Jordan. *The American*
470 *journal of tropical medicine and hygiene*, 101(1), 40–44.
471
- 472 24. Selmi R, Mamlouk A, Ben Yahia H, Abdelaali H, Ben Said M, Sellami K, Daaloul-Jedidi M,
473 Jemli MH, Messadi L. *Coxiella burnetii* in Tunisian dromedary camels (*Camelus*
474 *dromedarius*): Seroprevalence, associated risk factors and seasonal dynamics. *Acta Trop.*
475 2018 Dec;188:234-239.
476

- 477 25. Janati Pirouz H, Mohammadi G, Mehrzad J, Azizzadeh M, Nazem Shirazi MH.
478 Seroepidemiology of Q fever in one-humped camel population in northeast Iran. *Trop*
479 *Anim Health Prod.* 2015 Oct;47(7):1293-8.
480
- 481 26. Devaux, C. A., Osman, I. O., Million, M., & Raoult, D. (2020). *Coxiella burnetii* in Dromedary
482 Camels (*Camelus dromedarius*): A Possible Threat for Humans and Livestock in North
483 Africa and the Near and Middle East?. *Frontiers in veterinary science*, 7, 558481.
484
- 485 27. Mohammadpour R, Champour M, Tuteja F, Mostafavi E. Zoonotic implications of camel
486 diseases in Iran. *Vet Med Sci.* 2020 Aug;6(3):359-381
487
- 488 28. Vellema P, Santman-Berends I, Dijkstra F, van Engelen E, Aalberts M, Ter Bogt-Kappert C,
489 van den Brom R. Dairy Sheep Played a Minor Role in the 2005-2010 Human Q Fever
490 Outbreak in The Netherlands Compared to Dairy Goats. *Pathogens.* 2021 Dec
491 3;10(12):1579.
492
- 493 29. Coxevac, inactivated *Coxiella burnetii* vaccine, European medicines agency,
494 <https://www.ema.europa.eu/en/medicines/veterinary/EPAR/coxevac>
495
- 496 30. Hogerwerf, L., van den Brom, R., Roest, H. I., Bouma, A., Vellema, P., Pieterse, M.,
497 Dercksen, D., & Nielen, M. (2011). Reduction of *Coxiella burnetii* prevalence by
498 vaccination of goats and sheep, The Netherlands. *Emerging infectious diseases*, 17(3),
499 379–386.
500
- 501 31. Musallam II, Abo-Shehada MN, Hegazy YM, Holt HR, Guitian FJ. Systematic review of
502 brucellosis in the Middle East: disease frequency in ruminants and humans and risk
503 factors for human infection. *Epidemiol Infect.* 2016 Mar;144(4):671-85.
504
- 505 32. Bardenstein, S., Gibbs, R. E., Yagel, Y., Motro, Y., & Moran-Gilad, J. (2021). Brucellosis
506 Outbreak Traced to Commercially Sold Camel Milk through Whole-Genome Sequencing,
507 Israel. *Emerging Infectious Diseases*, 27(6), 1728-1731.
508
- 509 33. Mumcuoglu KY, Arslan-Akveran G, Aydogdu S, Karasartova D, Kosar N, Gureser AS,
510 Shacham B, Taylan-Ozkan A. Pathogens in ticks collected in Israel: I. Bacteria and protozoa
511 in *Hyalomma aegyptium* and *Hyalomma dromedarii* collected from tortoises and camels.
512 *Ticks Tick Borne Dis.* 2022 Jan;13(1):101866
513
- 514 34. Getange D, Bargul JL, Kanduma E, Collins M, Bodha B, Denge D, Chiuya T, Githaka N,
515 Younan M, Fèvre EM, Bell-Sakyi L, Villinger J. Ticks and Tick-Borne Pathogens Associated
516 with Dromedary Camels (*Camelus dromedarius*) in Northern Kenya. *Microorganisms.*
517 2021 Jun 30;9(7):1414
518
- 519 35. el-Azazy OM. Camel tick (Acari:Ixodidae) control with pour-on application of flumethrin.
520 *Vet Parasitol.* 1996 Dec 31;67(3-4):281-4.

